Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Brayer · SciRah

Researcher profile · Semantic Scholar

J. Brayer

Share profile

J. Brayer — researcher profile on SciRah

h-index: 25
Works: 104
Citations: 3,752

Most-cited papers

Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses
P. Rodriguez, D. Quiceno, J. Zabaleta, Blair Ortiz +9 more
2004Cancer Research1,270 citations Open access
Semantic Scholar
A critical role for Stat3 signaling in immune tolerance.
F. Cheng, Hong-Wei Wang, A. Cuenca, Mei-Juan Huang +9 more
2003Immunity420 citations Open access
Semantic Scholar
A Dual Role for Interferon‐γ in the Pathogenesis of Sjögren's Syndrome‐Like Autoimmune Exocrinopathy in the Nonobese Diabetic Mouse
S. Cha, J. Brayer, Jue-Hua Gao, V. Brown +3 more
2004Scandinavian Journal of Immunology166 citations
Semantic Scholar
Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice.
Kim H. T. Nguyen, J. Brayer, S. Cha, S. Diggs +4 more
2000Arthritis & Rheumatism137 citations
Semantic Scholar
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
A. Cuenca, F. Cheng, Hongwei Wang, J. Brayer +6 more
2003Cancer Research127 citations
Semantic Scholar
Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses1
Tomar Ghansah, Kim H. T. Paraiso, Steven L. Highfill, C. Desponts +8 more
2004Journal of Immunology113 citations Open access
Semantic Scholar
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
D. Sallman, T. Kerre, V. Havelange, X. Poiré +15 more
2023The Lancet Haematology93 citations Open access
Semantic Scholar
IL‐4‐Dependent Effector Phase in Autoimmune Exocrinopathy as Defined by the NOD.IL‐4‐Gene Knockout Mouse Model of Sjögren's Syndrome
J. Brayer, S. Cha, H. Nagashima, U. Yasunari +6 more
2001Scandinavian Journal of Immunology91 citations Open access
Semantic Scholar
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
J. Logue, L. Peres, Hamza Hashmi, Christelle M. Colin-Leitzinger +31 more
2022Blood Advances88 citations Open access
Semantic Scholar
Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjögren's syndrome-like autoimmune exocrinopathy.
J. Brayer, J. Lowry, S. Cha, C. P. Robinson +3 more
2000Journal of Rheumatology81 citations
Semantic Scholar
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
D. Sallman, J. Brayer, Elizabeth M. Sagatys, C. Lonez +6 more
2018Haematologica79 citations Open access
Semantic Scholar
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
J. Brayer, J. Lancet, J. Powers, A. List +3 more
2015American journal of hematology/oncology63 citations Open access
Semantic Scholar
Abnormal Organogenesis in Salivary Gland Development May Initiate Adult Onset of Autoimmune Exocrinopathy
S. Cha, Saskia C. A. van Blockland, M. Versnel, F. Homo-Delarche +4 more
2001Experimental and Clinical Immunogenetics62 citations
Semantic Scholar
TLR5 Ligation by Flagellin Converts Tolerogenic Dendritic Cells into Activating Antigen-Presenting Cells that Preferentially Induce T-Helper 1 Responses
Ildelfonso Vicente-Suarez, J. Brayer, A. Villagra, F. Cheng +1 more
2009Immunology Letters58 citations Open access
Semantic Scholar
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
D. Madduri, A. Rosko, J. Brayer, J. Zonder +16 more
2020Blood53 citations Open access
Semantic Scholar
Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
Shaji K. Kumar, Rachid C. Baz, R. Orlowski, L. Anderson +8 more
202053 citations Open access
Semantic Scholar
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
P. Horna, A. Cuenca, F. Cheng, J. Brayer +4 more
2006Blood51 citations Open access
Semantic Scholar
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
C. Lonez, Bikash K. Verma, A. Hendlisz, P. Aftimos +12 more
2017BMJ Open44 citations Open access
Semantic Scholar
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
J. Zonder, J. Richter, N. Bumma, J. Brayer +13 more
2021Blood36 citations Open access
Semantic Scholar
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
N. Bumma, J. Richter, J. Brayer, J. Zonder +16 more
2022Blood32 citations Open access
Semantic Scholar
Elevated proapoptotic Bax and caspase 3 activation in the NOD.scid model of Sjögren's syndrome.
R. Masago, S. Aiba-Masago, N. Talal, F. J. Zuluaga +7 more
2001Arthritis & Rheumatism31 citations
Semantic Scholar
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
D. H. Lee, Abhishek Kumar, T. Mohammed, L. Peres +24 more
2023Blood Advances27 citations Open access
Semantic Scholar
Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma
L. Peres, Christelle M. Colin-Leitzinger, Mingxiang Teng, J. Dutil +15 more
2022Blood Advances25 citations Open access
Semantic Scholar
Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
D. Sallman, J. Brayer, X. Poiré, V. Havelange +11 more
2019Blood25 citations Open access
Semantic Scholar
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma
J. Brayer, R. Baz
2017Therapeutic Advances in Hematology25 citations Open access
Semantic Scholar
Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform
A. Al-Homsi, S. Anguille, D. Deeren, T. Nishihori +11 more
2021Blood24 citations Open access
Semantic Scholar
Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy
D. Sallman, T. Kerre, X. Poiré, V. Havelange +12 more
2018Blood24 citations Open access
Semantic Scholar
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
A. Mostofa, Allison Distler, M. Meads, Eva Sahakian +27 more
2021JCI Insight22 citations Open access
Semantic Scholar
ENHANCED CD8 T CELL CROSS-PRESENTATION BY MACROPHAGES WITH TARGETED DISRUPTION OF STAT3
J. Brayer, F. Cheng, Hongwei Wang, P. Horna +3 more
2010Immunology Letters20 citations Open access
Semantic Scholar
Sjögren's syndrome: immunological response underlying the disease.
J. Brayer, M. Humphreys-Beher, A. Peck
2001Archivum Immunologiae et Therapiae Experimentalis17 citations
Semantic Scholar
Developing Strategies in the Immunotherapy of Leukemias
J. Brayer, J. Pinilla-Ibarz
2013Cancer Control: Journal of the Moffitt Cancer Cente15 citations Open access
Semantic Scholar
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
C. Freeman, R. Atkins, I. Varadarajan, M. Menges +15 more
2023Clinical Cancer Research14 citations
Semantic Scholar
High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
Ricardo Villanueva, Doris K. Hansen, R. Tonseth, K. Gage +15 more
2022Blood13 citations Open access
Semantic Scholar
The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
T. Nishihori, M. Alsina, J. Ochoa, O. Castaneda Puglianini +7 more
2019Blood11 citations Open access
Semantic Scholar
Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)
R. Baz, J. Zonder, K. Shain, M. Alsina +6 more
201711 citations
Semantic Scholar
Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).
R. Baz, K. Shain, M. Alsina, J. Brayer +5 more
201610 citations
Semantic Scholar
Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.
J. Brayer, M. Fishman
2014Journal of immunotherapy9 citations
Semantic Scholar
Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma
A. Al-Homsi, S. Anguille, J. Brayer, D. Deeren +11 more
20208 citations Open access
Semantic Scholar
Immunogenetics of autoimmune exocrinopathy in the nod mouse: more than meets the eye.
M. Humphreys-Beher, J. Brayer, S. Cha, Hiroyuki Nagashima +2 more
2000Advances in Experimental Medicine and Biology8 citations
Semantic Scholar
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.
M. Meads, Xiao-Hong Zhao, D. Noyes, P. Sudalagunta +23 more
2025Blood6 citations
Semantic Scholar
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma
P. Sudalagunta, R. Canevarolo, M. Meads, Maria Silva +33 more
2024Cancer Research6 citations Open access
Semantic Scholar
Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
Nathan H. Parker, Karnav Modi, Ricardo Villanueva, Lawrence Skelson +19 more
2022Blood6 citations Open access
Semantic Scholar
Reinforcement Learning to Optimize the Treatment of Multiple Myeloma
K. Shain, D. Hart, Ariosto S. Siqueira Silva, R. Alugubelli +12 more
2019Blood6 citations Open access
Semantic Scholar
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis
A. Grajales-Cruz, Cristian Ivan Rodriguez Arocho, A. Rose, J. Shapiro +8 more
2019Blood6 citations Open access
Semantic Scholar
Abstract CT129: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute myeloid leukemia
D. Sallman, J. Brayer, X. Poiré, T. Kerre +9 more
2018Clinical Trials6 citations
Semantic Scholar
Enhancing synergy of CAR T cell therapy and oncolytic virus therapy for pancreatic cancer
R. Walker, Pedro Navas, Samuel H. Friedman, S. Galliani +11 more
2016bioRxiv6 citations Open access
Semantic Scholar
OMIP: Analysis of Human Myelopoiesis and Myeloid Neoplasms
Genyuan Zhu, J. Brayer, E. Padron, J. Mulé +1 more
2018Cytometry Part A5 citations Open access
Semantic Scholar
S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
J. Zonder, J. Richter, N. Bumma, J. Brayer +14 more
2022HemaSphere4 citations Open access
Semantic Scholar
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study
Yu-Meng Zhang, L. Duncanson, J. Brayer, Frederic J. Reu +9 more
2022Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types.
Bikash K. Verma, P. Aftimos, A. Awada, J. Machiels +7 more
20174 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Shain×15
Invite
K. Shain — researcher profile on SciRah
T. Nishihori×13
Invite
T. Nishihori — researcher profile on SciRah
R. Baz×13
Invite
R. Baz — researcher profile on SciRah
M. Alsina×12
Invite
M. Alsina — researcher profile on SciRah

×9

Invite

C. Lonez — researcher profile on SciRah

E. Sotomayor×8

Invite

E. Sotomayor — researcher profile on SciRah

Invite

F. Lehmann — researcher profile on SciRah

M. Humphreys-Beher×7

Invite

M. Humphreys-Beher — researcher profile on SciRah

Invite

D. Sallman — researcher profile on SciRah

Invite

D. Gilham — researcher profile on SciRah

Brandon Blue×7

Invite

Brandon Blue — researcher profile on SciRah

Invite

F. Cheng — researcher profile on SciRah